Abstract
On September 21 and 22, 2006, the National Institute of Child Health and Human Development of the National Institutes of Health sponsored a 2-day workshop titled “Preeclampsia—A Pressing Problem.” The purpose of the workshop was to bring together leaders in the field to present and discuss their diverse research areas, which ranged from basic science to clinical trials and management, and to identify scientific gaps. This article is a summary of the proceedings of that workshop. Although much progress is being made in understanding the underpinnings of preeclampsia, a number of research gaps are identified that, if filled, would hasten progress in the field. It is the overall consensus that preeclampsia is a multifactorial disease whose pathogenesis is not solely vascular, genetic, immunologic, or environmental but a complex combination of factors. In addition, a number of specific scientific gaps are identified including insufficient multidisciplinary and collaborative research, clinical trials and studies of patient management, and a lack of in-depth mechanistic research. The research community needs to focus on these gaps to better understand the disease, with the ultimate goal of preventing the disorder.
Similar content being viewed by others
References
Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F., Kirmeyer S. Births: final data for 2004. Natl Vital Stat Rep. 2006;55.
Meis PJ, Goldenberg RL, Mercer BM, et al. The Preterm Prediction Study: risk factors for indicated preterm births. Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am J Obstet Gynecol. 1998;178:562–567.
Stella CL, Sibai BM Preeclampsia: diagnosis and management of the atypical presentation. J Matern Fetal Neonatal Med. 2006;19:381–386.
Meekins JW, Pijnenborg R., Hanssens M., McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1994;101:669–674.
Lyall F. The human placental bed revisited. Placenta. 2002; 23:555–562.
Roberts JM, Gammill HS Preeclampsia: recent insights. Hypertension. 2005;46:1243–1249.
Kim YM, Chaiworapongsa T., Gomez R., et al. Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol. 2002;187:1137–1142.
Kim YM, Bujold E., Chaiworapongsa T., et al. Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol. 2003;189:1063–1069.
Hung TH, Skepper JN, Burton GJ In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies. Am J Pathol. 2001;159: 1031–1043.
Davidge ST Oxidative stress and altered endothelial cell function in preeclampsia. Semin Reprod Endocrinol. 1998;16:65–73.
Chappell LC, Seed PT, Briley AL, et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet. 1999;354:810–816.
Poston L., Briley AL, Seed PT, Kelly FJ, Shennan AH; Vitamins in Pre-eclampsia Trial Consortium. Vitamin C and E in pregnant women at risk for pre-eclampsia (VIP Trial): randomised placebo controlled trial. Lancet. 2006;367:145–154.
Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS; for the ACTS Study Group. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med. 2006;354:1796–1806.
Li DK, Wi S. Changing paternity and the risk of preeclampsia/eclampsia in the subsequent pregnancy. Am J Epidemiol. 2000;151:57–62.
Wallukat G., Homuth V., Fischer T., et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945–952.
Walther T., Wallukat G., Janik A., et al. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 2005;46:1275–1279.
Redman Cwg, Sargent IL Pre-eclampsia, the placenta and the maternal systemic inflammatory response. Placenta. 2003;24(suppl A):S24–S27.
Hanna J., Goldman-Wohl D., Hamani Y., et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006;12:1065–1074.
Levine RJ, Maynard SE, Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683.
Levine RJ, Lam C., Qian C., et al; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;350:992–1005.
Zintzaras E., Kitsios G., Harrison GA, et al. Heterogeneity-based genome search meta-analysis for preeclampsia. Hum Genet. 2006;120:360–370.
Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet. 2005;353:785–799.
Basso O., Christensen K., Olsen J. Higher risk of pre-eclampsia after change of partner: an effect of longer interpregnancy intervals? Epidemiology. 2001;2:624–629.
Saftlas AF, Levine RJ, Klebanoff MA, et al. Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol. 2003;57:108–114.
Triche EW, Saftlas AF, Belanger K., Leaderer BP, Bracken MB Association between asthma diagnosis, severity, symptoms, and treatment in pregnancy with risk of preeclampsia. Obstet Gynecol. 2004;104:585–593.
Saftlas AF, Logsden-Sackett N., Wang W., Woolson R., Bracken MB Work, leisure-time physical activity, and risk of preeclampsia and gestational hypertension. Am J Epidemiol. 2004;160:758–765.
Sorensen TK, Williams MA, Lee IM, Dashow EE, Thompson ML, Luthy DA Recreational physical activity during pregnancy and risk of preeclampsia. Hypertension. 2003;41:1273–1280.
Chesley LC Hypertensive Disorders of Pregnancy. New York, NY: Appleton-Century-Crofts; 1978.
Roberts JM, Bodnar LM, Lain KY, et al. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension. 2005;46:1263–1269.
Irgens HU, Reisaeter L., Irgens LM, Lie RT Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001;323:1213–1217.
Funai EF, Paltiel OB, Malaspina D., Friedlander Y., Deutsch L., Harlap S. Risk factors for pre-eclampsia in nulliparous and parous women: the Jerusalem Perinatal Study. Paediatr Perinat Epidemiol. 2005;19:59–68.
Chesley LC, Annitto JE, Cosgrove RA The remote prognosis of eclamptic women. Am J Obstet Gynecol. 1976;124:446–459.
Fisher KA, Luger A., Spargo BH, Lindheimer MD Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine. 1981;60:267–276.
Xiong X., Fraser WD Impact of pregnancy-induced hypertension on birthweight by gestational age. Paediatr Perinat Epidemiol. 2004;18;186–191.
Sibai BM, Mercer B., Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol. 1991;165:1408–1412.
Lain KY, Krohn MA, Roberts JM Second pregnancy outcomes following preeclampsia in a first pregnancy. Hypertens Pregnancy. 2005;24:159–169.
DiFederico E., Genbacev O., Fisher SJ Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am J Pathol. 1999;155:293–301.
Zhou Y., Damsky CH, Fisher SJ Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype: one cause of defective endovascular invasion in this syndrome? J Clin Invest. 1997;99:2152–2164.
Damsky CH, Fisher SJ Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors. Curr Opin Cell Biol. 1998;10:660–666.
Zhou Y., McMaster M., Woo K., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002;160:1405–1423.
Zhou Y., Bellingard V., Feng KT, McMaster M., Fisher SJ Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of Ang2, PlGF, and VEGF-C. Dev Biol. 2003;263:114–125.
Mayhew TM, Wijesekara J., Baker PN, Ong SS Morphometric evidence that villous development and fetoplacental angiogenesis are compromised by intrauterine growth restriction but not by pre-eclampsia. Placenta. 2004;25:829–833.
Mayhew TM Patterns of villous and intervillous space growth in human placentas from normal and abnormal pregnancies. Eur J Obstet Gynecol Reprod Biol. 1996;68:75–82.
Egbor M., Ansari T., Morris N., Green CJ, Sibbons PD Preeclampsia and foetal growth restriction: how morphometrically different is the placenta? Placenta. 2005;27:727–734.
Egbor M., Ansari T., Morris N., Green CJ, Sibbons PD Morphometric placental villous and vascular abnormalities in early and late-onset pre-eclampsia with and without fetal growth restriction. Br J Obstet Gynaecol. 2005;113:580–589.
Meerarani P., Badimon JJ, Zias E., Fuster V., Moreno PR Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications. Curr Mol Med. 2006;6: 501–514.
Redman Cwg, Sacks GP, Sargent IL Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180:499–506.
Sacks GP, Seyani L., Lavery S., Trew G. Maternal C-reactive protein levels are raised at 4 weeks gestation. Hum Reprod. 2004;19:1025–1030.
Germain SJ, Sacks GP, Soorana SR, Sargent IL, Redman CW Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol. 2007;178:5949–5956.
Smarason AK, Sargent IL, Starkey PM, Redman Cwg. The effect of placental syncytiotrophoblast microvillous membranes from normal and pre-eclamptic women on the growth of endothelial cells in vitro. Br J Obstet Gynaecol. 1993;100: 943–949.
Moffett A., Loke C. Immunology of placentation in eutherian mammals. Nat Rev Immunol. 2006;6:584–594.
Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol. 2002;2:656–663.
Hiby SE, Walker JJ, O’Shaughnessy KM, Redman CW, Carrington M, Trowsdale J, Moffett A. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med. 2004;200: 957–965.
Dechend R., Homuth V., Wallukat G., et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation. 2000;101:2382–2387.
Dechend R., Viedt C., Muller DN, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation. 2003;107:1632–1639.
Xia Y., Wen H., Bobst S., Day MC, Kellems RE Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig. 2003;10:82–93.
Rajakumar A., Brandon HM, Daftary A., Ness R., Conrad KP Evidence for the functional activity of hypoxia inducible transcription factors overexpressed in preeclamptic placentae. Placenta. 2004;25:763–769.
Ness RB, Sibai BM Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. 2006;195:40–49.
Mayhew TM, Charnock-Jones DS, Kaufmann P. Aspects of human fetoplacental vasculogenesis and angiogenesis. III. Changes in complicated pregnancies. Placenta. 2004;25:127–139.
Rajakumar AR, Jeyabalan A., Markovic N., Ness R., Gilmore C., Conrad KP Placental HIF-1α, HIF-2α, membrane and soluble VEGF receceptor-1 are not increased in normotensive pregancies complicated by late onset intrauterine growth restriction. Am J Physiol. Epub ahead of print May 16, 2007.
Levine D. Science to practice: can MR oxygenation imaging be used to assess at-risk pregnancies? Radiology. 2006;238:872–880.
Kakogawa J., Sumimoto K., Ho E., Kanayama N. Transabdominal measurement of oxygenation of the placenta by near-infrared spectroscopy. Semin Thromb Hemost. 2005;31:3297–3301.
Novak JN, Conrad KP Emerging role of relaxin in cardiovascular and renal function. Am J Physiol Regul Integr Comp Physiol. 2004;287:R250–R261.
Ness RB, Hubel CA Risk for coronary artery disease and morbid preeclampsia: a commentary. Ann Epidemiol. 2005;15: 726–733.
Bodnar LM, Catov JM, Klebanoff MA, Ness RB, Roberts JM Prepregnancy body mass index and the occurrence of severe hypertensive disorders of pregnancy. Epidemiology. 2007;18:234–239.
Catov JM, Ness RB, Kip KE, Olsen J. Risk of early or severe preeclampsia related to preexisting conditions. Int J Epidemiol. Epub ahead of print January 25, 2007.
Villamor E., Cnattinguis S. Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-based study. Lancet. 2006;368:1164–1170.
Funai EF, Friedlander Y., Paltiel O., et al. Long-term mortality after preeclampsia. Epidemiology. 2005;16:206–215.
Hubel CA, Snaedal S., Ness RB, et al. Dyslipoproteinemia in postmenopausal women with a history of eclampsia. Br J Obstet Gynaecol. 2000;107:776–784.
Maynard SE, Min JY, Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–658.
Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–649.
Chappell S., Morgan L. Searching for genetic clues to the causes of pre-eclampsia. Clin Sci (Lond). 2006;10:443–458.
Zhang XQ, Craven C., Nelson L., Varner MW, Ward KJ Placental abruption is more frequent in women with the angiotensinogen Thr235 mutation. Placenta. 2007;28:616–619.
Oudejans CB, van Dijk M., Oosterkamp M., Lachmeijer A., Blankenstein MA Genetics of preeclampsia: paradigm shifts. Hum Genet. 2007;120:607–612.
Stella C., Sibai BM Thrombophilia and adverse maternal-perinatal outcome: controversies in screening and management. Am J Perinatol. 2006;23:499–506.
Lin L., August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol. 2005;105:182–192.
Mello G., Parretti E., Marozio L., et al. Thrombophilias is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension. 2005;46: 1270–1274.
Robertson L., Wu O., Laughorne P., et al.Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2005;32:171–196.
Roberts JM, Balk JL, Bodnar LM, Belizan JM, Bergel E., Martinez A. Nutrient involvement in preeclampsia. J Nutr. 2003;133:1684S–1692S.
Chung R., Davis H., Ma Y., Naivikul O., Williams C., Wilson K. Diet related toxemia in pregnancy. Am J Clin Nutr. 1979;32: 1902–1911.
Morris CD, Jacobson SL, Anand R., et al. Nutrient intake and hypertensive disorders of pregnancy: evidence from a large prospective cohort. Am J Obstet Gynecol. 2001;184:643–651.
Bodnar LM, Tang G., Ness RB, Harger G., Roberts JM Periconceptional multivitamin use reduces risk of preeclampisa. Am J Epidemiol. 2006;164:470–477.
Scholl TO, Leskiw M., Chen X., Sims M., Stein TP Oxidative stress, diet, and the etiology of preeclampsia. Am J Clin Nutr. 2005;81:1390–1396.
Salafia CM, Pezzullo JC, Ghidini A., Lopez-Zeno JA, Whittington SS Clinical correlations of patterns of placental pathology in preterm pre-eclampsia. Placenta. 1998;19:67–72.
Ghidini A., Salafia CM, Pezzullo JC Placental vascular lesions and likelihood of diagnosis of preeclampsia. Obstet Gynecol. 1997;90:542–545.
Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol. 2005; 193:429–436.
Conde-Agudelo A., Villar J., Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol. 2004;104:1367–1391.
Gomez O., Martinez JM, Figueras F., et al. Uterine artery Doppler at 11–14 weeks of gestation to screen for hypertensive disorders and associated complications in an unselected population. Ultrasound Obstet Gynecol. 2005;26:490–494.
Levine RJ, Qian C., Maynard SE, Yu KF, Epstein FH, Karumanchi SA Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol. 2006;194:1034–1041.
Levine RJ, Thadhani R., Qian C., et al. Urinary placental growth factor and risk of preeclampsia. JAMA. 2005;293:77–85.
Buhimschi CS, Norwitz ER, Funai E., Guller S., Lockwood C., Buhimschi I. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol. 2005;192:743–741.
Williams WW, Ecker JL, Thadhani RI, Rahemtullah A. Case 38-2005: a 29-year-old pregnant woman with the nephrotic syndrome and hypertension. N Engl J Med. 2005;353: 2590–2600.
Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med. 1997;337:69–76.
Caritis S., Sibai B., Hauth J., et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med. 1998;338: 701–705.
Raijmakers MT, Dechend R., Poston L. Oxidative stress and preeclampsia: rationale for antioxidant clinical trials. Hypertension. 2004;44:374–380.
Cui XL, Brockman D., Campos B., Myatt L. Expression of NADPH oxidase isoform 1 (Nox1) in human placenta: involvement in preeclampsia. Placenta. 2006;27:422–431.
Myatt L., Rosenfield RB, Eis AL, Greer I., Lyall F. Nitrotyrosine residues in placenta: evidence of peroxynitrite formation and action. Hypertension. 1996;28:488–493.
Chappell LC, Seed PT, Briley A., et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol. 2002;187:127–136.
Sibai BM Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102:181–192.
Report of the National High Blood Pressure Education Program. Working group report on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S1–22.
Sibai BM, Barton JR Dexamethasone to improve maternal outcome in women with HELLP syndrome. Am J Obstet Gynecol. 2005;193:1587–1590.
Ganzevoert W., Rep A., Bousel GJ, et al. A randomized controlled trial comparing two temporising management strategies for severe preeclampsia. BJOG. 2005;112:1358–1368.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ilekis, J.V., Reddy, U.M. & Roberts, J.M. Preeclampsia—A Pressing Problem: An Executive Summary of a National Institute of Child Health and Human Development Workshop. Reprod. Sci. 14, 508–523 (2007). https://doi.org/10.1177/1933719107306232
Published:
Issue Date:
DOI: https://doi.org/10.1177/1933719107306232